Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/1b Open-Label Multi-Center to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Metastatic or Locally-Advanced Solid Tumor or Lymphoma

    Cancer Categories
    • Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2018-154
    NCT ID
    • NCT03815682
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator


    Primary Objective:
    • To characterize the safety and tolerability TRQ15-01 and to identify recommended doses and schedules for future studies
    Secondary Objectives
    • To characterize changes in the immune infiltrate in tumors
    • To further characterize the safety of TRQ15-01
    • To characterize the pharmacokinetics of TRQ15-01
    • To assess immunogenicity of TRQ15-01
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266